Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025

Key Takeaway: SI-BONE, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will feature a fireside chat hosted by the company's management. Interested investors can register for the event and access the live audio webcast on the company's website, which will also be archived for later viewing.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is participating in a prominent investor conference.
  • The company has a strong track record with over 125,000 procedures performed.
  • Management will engage directly with investors through a fireside chat.

Full Press Release Details

SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45thAnnual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:https://wsw.com/webcast/canaccord108/sibn/2510356. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,600 physicians in performing a total of over 125,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE,Sacropelvic Solutions,iFuse Implant System®, iFuse Bedrock Granite,andiFuse TORQ, are registered trademarks, andiFuse 3D, iFuse TORQ TNT, andiFuse INTRAare trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbalinvestors@si-bone.com

Frequently Asked Questions

When is SI-BONE's presentation at the conference?

SI-BONE's presentation is scheduled for August 12, 2025.

How can investors listen to the conference call?

Investors can register for the conference call through the provided link.

What is SI-BONE known for?

SI-BONE specializes in technologies for surgical treatment of sacropelvic disorders.

Where can I find the archived webcast?

The archived webcast will be available on SI-BONE's website for at least 90 days.

Last updated: Jul 29, 2025